When it comes to the advantage that emerging coronavirus stocks have over their more established counterparts, the author of today’s article notes that, “While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks.” He proceeds to take a look at four such emerging coronavirus stocks – and why he believes that “investing $3,000 in any combination of them is a good idea.” CLICK HERE.
